文献速递临床试验与 GCP

奈必洛尔与卡维地洛对老年射血分数保留心力衰竭患者左心室舒张功能影响的比较:一项随机对照试验的研究方案

Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2016-11-03

本试验为前瞻性、随机、开放标签、单中心、阳性对照研究,计划纳入62例新诊断的老年心力衰竭患者(LVEF≥40%、NYHA I-III级、近3个月无因心衰住院),按1:1随机接受奈必洛尔或卡维地洛治疗,在基线、6个月和12个月进行超声心动图评估,检验奈必洛尔改善左心室舒张功能优于卡维地洛的假设,预计2017年获得结果。

要点

  • 针对70岁以上、LVEF≥40%的老年心衰患者,比较奈必洛尔与卡维地洛对左心室舒张功能的影响。
  • 计划纳入62例新诊断心衰患者,1:1随机分组,随访至12个月。
  • 主要评估时间点为基线、治疗后6个月和12个月,采用超声心动图评价舒张功能。

核心结论

  • 本试验旨在评估奈必洛尔对左心室舒张功能的影响,并为射血分数保留的心衰患者诊断后管理中β受体阻滞剂的最佳选择提供信息。
  • 研究结果预计于2017年获得。

研究设计与样本

  • 前瞻性、随机、开放标签、单中心、阳性对照研究。
  • 计划纳入62例新诊断心力衰竭的老年患者。
  • 纳入标准包括左心室射血分数(LVEF)≥40%、纽约心脏协会(NYHA)功能分级I、II或III级,且前3个月内临床稳定、未因心衰住院。
  • 符合条件患者按1:1比例随机接受奈必洛尔或卡维地洛的负荷剂量和维持剂量治疗。
  • 在基线、治疗后6个月和12个月进行超声心动图评估,并在固定时间进行临床评估和实验室检查。

关键数值与推荐

  • LVEF≥40%
  • NYHA功能分级I、II或III级
  • 前3个月内临床稳定且未因心衰住院

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart failure (HF) is a common and disabling condition in older people. Randomized clinical trials and meta-analyses have clearly demonstrated that the long-term use of β-Blockers improves the outcome of patients with HF. However, limited data are available on the treatment of older HF patients with preserved ejection fraction (EF). No study has specifically compared the relative effectiveness of carvedilol and nebivolol in treating HF in older patients with preserved EF. METHOD/DESIGN: This trial is a prospective, randomized, open-label, single-centre, active controlled study designed to investigate the effects of nebivolol and carvedilol on diastolic function of the left ventricle (LV) in older HF patients with preserved EF. We will test the hypothesis that nebivolol improves LV diastolic function to a greater extent than carvedilol in patients over 70 years of age. The study population includes 62 older patients newly diagnosed with HF. Patients will be included in the study if they have a LVEF ≥40 %, New York Heart Association (NYHA) functional classes I, II or III status, and have been clinically stable without hospital admission for HF in the preceding 3 months. Eligible patients will be randomly assigned, in a 1:1 ratio, to receive a loading and maintenance dose of either nebivolol or carvedilol. Echocardiographic evaluations will be performed at baseline, 6, and 12 months after therapy. Clinical assessment and laboratory tests are to be performed at fixed times. DISCUSSION: This trial is a single-center study that aims to evaluate the impact of nebivolol on LV diastolic function. The results of the study will provide information about the optimal choice of a β-Blocker in the management of patients after diagnosis of HF with preserved EF. The results will be available by 2017. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02619526 , registered on 25 November 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Park K, Park TH. Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. Trials. 2016. PMID: 27809882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。